Zyagnum AG
Johannes Coy is an experienced entrepreneur and executive in the biotechnology and medical fields, currently serving as the CEO of Oxy5 OncoMedical AG and leading benfovir AG since June 2020. With a strong academic background in biology from the University of Tübingen and the DKFZ German Cancer Research Center, Johannes has founded multiple companies, including intelligent sugar GmbH, Zyagnum AG, TAVARGENIX GmbH, and TAVARTIS GmbH, all focused on innovative approaches to cancer diagnosis and treatment, as well as the development of functional sugars. Past roles include Head of Oncology at R-Biopharm AG and Head of Target Identification at mtm laboratories, contributing significantly to advancements in cancer research and diagnostics.
This person is not in any teams
Zyagnum AG
We are convinced that early detection of diseases is the prerequisite for better treatment options and thus optimal chances of recovery. That is why we are driven by the vision of making chronic health imbalances diagnosable even before the disease can manifest itself. This is the prerequisite for turning the early detection of life-changing diseases such as cancer, Alzheimer’s or diabetes into true prevention. Our aim is to make our diagnostics as simple, cost-effective, and burden-free as possible so that as many people as possible can benefit from them. Imprint: https://www.zyagnum.com/en/imprint/ Privacy Policy: https://bit.ly/3d1YHzO